MARKET

CLSD

CLSD

Clearside
NASDAQ

Real-time Quotes | Nasdaq Last Sale

3.410
-0.040
-1.16%
After Hours: 3.410 0 0.00% 16:00 03/02 EST
OPEN
3.570
PREV CLOSE
3.450
HIGH
3.580
LOW
3.304
VOLUME
318.48K
TURNOVER
--
52 WEEK HIGH
4.530
52 WEEK LOW
1.100
MARKET CAP
178.81M
P/E (TTM)
-10.7537
1D
5D
1M
3M
1Y
5Y
News
Financial
Releases
Corp Actions
Analysis
Profile
Clearside Biomedical (CLSD) Gets a Buy Rating from Wedbush
Wedbush analyst Liana Moussatos reiterated a Buy rating on Clearside Biomedical (CLSD) today and set a price target of $6.00. The company's shares closed
SmarterAnalyst · 9h ago
Clearside Biomedical completes dosing in early-stage wet AMD study cohort 1
Clearside Biomedical (CLSD) announces completion of dosing in the first cohort of OASIS, its ongoing Phase 1/2a clinical trial of CLS-AX (axitinib injectable suspension) in patients with neovascular age-related macular
Seekingalpha · 13h ago
Clearside Biomedical Announces Completion of Patient Dosing in First Cohort of Phase 1/2a Clinical Trial of CLS-AX (axitinib injectable suspension) for the Treatment of Wet AMD
ALPHARETTA, Mar 02, 2021 (GLOBE NEWSWIRE via COMTEX) -- - Initial Safety Data from First Cohort Expected Mid-2021 - ALPHARETTA, Ga., March 02, 2021 (GLOBE...
GlobeNewswire · 14h ago
Uveitis Treatment Market Size, Share, Growth, Research and Forecast 2020-2026
Mar 02, 2021 (Market Insight Reports) -- The global uveitis treatment market is projected to exhibit a significant growth, at a CAGR of around 6.1%, during...
Market Insight Reports · 14h ago
Global Anterior Uveitis Treatment Market Size By End User, By Region 2021 | Overview, Growth, Economics, Demand And Forecast Research Report To 2026
Mar 01, 2021 (The Expresswire) -- Global “Anterior Uveitis Treatment Market” (2021-2026) to its vast repository and growth prospects of the market provides...
The Express Wire · 1d ago
Horizon's (HZNP) Shares Rise on Q4 Earnings & Sales Beat
Zacks.com · 5d ago
Bayer's (BAYRY) Q4 Earnings Match Estimates, Sales Miss
Zacks.com · 5d ago
Bayer's (BAYRY) Q4 Earnings Match Estimates, Sales Miss
Zacks.com · 5d ago
More
Forecast
EPSBVPSCFPS
Actual (USD)
Estimate (USD)
Income StatementMore
Net IncomeTotal RevenueOperating Income
Net Income (USD)
YoY (%)
Balance SheetMore
Total Assets (USD)
Total Liabilities (USD)
Debt to Asset (%)
Cash FlowMore
OperatingInvestingFinancing
Operating (USD)
YoY (%)
Learn about the latest financial forecast of CLSD. Analyze the recent business situations of Clearside through EPS, BVPS, FPS, and other data. This information may help you make smarter investment decisions.
Analyst Rating

Based on 5 analysts

Buy

Disclaimer: The analysis information is for reference only and does not constitute an investment recommendation.

Analyst Price Target
The average CLSD stock price target is 6.38 with a high estimate of 8.00 and a low estimate of 3.500.
EPS
Institutional Holdings
Institutions: 87
Institutional Holdings: 16.99M
% Owned: 32.41%
Shares Outstanding: 52.44M
TypeInstitutionsShares
Increased
10
1.84M
New
13
-37.16K
Decreased
10
332.92K
Sold Out
0
0
  • Performance
  • Asset Allocation
  • Dividend History
No Data
Industry
Biotechnology & Medical Research
-2.09%
Pharmaceuticals & Medical Research
-0.90%
Key Executives
Chairman/Independent Director
Christy Shaffer
President/Chief Executive Officer/Director
George Lasezkay
Chief Financial Officer
Charles Deignan
Independent Director
Richard Croarkin
Independent Director
Jeffrey Edwards
Independent Director
William Humphries
Independent Director
Nancy Hutson
Independent Director
Clay Thorp
  • Dividends
  • Splits
  • Insider Activity
No Data
About CLSD
Clearside Biomedical, Inc. is a clinical biopharmaceutical company developing first-in-class drug therapies to treat blinding diseases of the eye. The Company's product candidates focus on diseases affecting three components of the eye: the retina, which is the tissue that lines the inside of the eye and is primarily responsible for vision; the choroid, which is the layer adjacent to the retina that supplies the retina with blood, oxygen and nourishment, and the sclera, which is the outer protective layer of the eye. The Company’s lead product candidate, XIPERE, is a proprietary, preservative-free suspension of the corticosteroid triamcinolone acetonide formulated for administration via suprachoroidal injection.

Webull offers kinds of Clearside Biomedical Inc stock information, including NASDAQ:CLSD real-time market quotes, financial reports, professional analyst ratings, in-depth charts, corporate actions, CLSD stock news, and many more online research tools to help you make informed decisions.

You can practice and explore trading CLSD stock methods without spending real money on the virtual paper trading platform.